person · Reporting owner

McDowell Caryn Gordon

Disclosed activity across 3 companies

Tapewire entity: 126407
SEC CIK: 0001674232

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CYTOKINETICS INCCYTK · Entity 3528	GC & Chief Compliance Officer	February 27, 2018	March 02, 2018
Quince Therapeutics, Inc.CRTX · Entity 7403	Chief Legal & Adm. Officer	June 06, 2022	June 08, 2022
Revance Therapeutics, Inc.RVNC · Entity 83521	SVP, GC & Secretary	February 15, 2020	February 19, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CYTOKINETICS INC

Report date February 27, 2018 · Filed March 02, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	35,000	Reported balance After 2018-02-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-02-27 · Grant · Acquired 20,000 · Balance 35,000 F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021.
Common StockSEC Table I · non-derivative	Direct	32,548	Reported balance After 2018-02-28 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2018-02-28 · Tax withholding · Disposed 2,452 · Balance 32,548
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27	Direct	15,226	Reported balance After 2018-02-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-02-27 · Grant · Acquired 15,226 · Balance 15,226 F2: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27	Direct	14,774	Reported balance After 2018-02-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-02-27 · Grant · Acquired 14,774 · Balance 14,774 F2: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021.

F2: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022.

Quince Therapeutics, Inc.

Report date June 06, 2022 · Filed June 08, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	122,500	Ending reported balance After 2022-06-06 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-06-06 · Tax withholding · Disposed 6,700 · Balance 133,300 F1: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2022-06-06 · Sale · Disposed 10,800 · Balance 122,500 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Revance Therapeutics, Inc.

Report date February 15, 2020 · Filed February 19, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,453	Reported balance After 2020-02-15 transaction · row 1 1 source row Row 1 · 2020-02-15 · Tax withholding · Disposed 864 · Balance 23,453 F1: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,500 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mrs. McDowell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. F2: The fair market value was determined on February 14, 2020 pursuant to the Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,500 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mrs. McDowell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.

F2: The fair market value was determined on February 14, 2020 pursuant to the Plan.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 06, 2022 Filed Jun 8, 2022 16:09 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	SaleCommon Stock	10,800	$2.86	$30,922.56	Disclosure SEC source: 0001209191-22-035014 · doc4.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 06, 2022 Filed Jun 8, 2022 16:09 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	Tax withholdingCommon Stock	6,700	$2.86	$19,183.44	Disclosure SEC source: 0001209191-22-035014 · doc4.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,300 F1 · shares: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 03, 2022 Filed Mar 4, 2022 17:57 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantCommon Stock	140,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-016441 · doc4.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant. Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:08 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantStock Option (right to buy) · Derivative	125,000	$0.00 Strike: $13.39	$0.00	Disclosure SEC source: 0001209191-22-001792 · doc4.xml · derivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. Read SEC document
December 11, 2020 Filed Dec 15, 2020 18:59 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $29.60	$0.00	Disclosure SEC source: 0001209191-20-063600 · doc4.xml · derivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F2 · derivative.exercise_date: 50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share. Read SEC document
December 11, 2020 Filed Dec 15, 2020 18:59 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $29.60	$0.00	Disclosure SEC source: 0001209191-20-063600 · doc4.xml · derivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date. Read SEC document
May 14, 2020 Filed May 15, 2020 17:37 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $45.88	$0.00	Disclosure SEC source: 0001209191-20-029819 · doc4.xml · derivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the stock option shall vest on May 5, 2021 with the remaining vesting monthly over the next 36 months. Read SEC document
February 15, 2020 Filed Feb 19, 2020 20:23 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	Tax withholdingCommon Stock	864	$25.33	$21,885.12	Disclosure SEC source: 0001479290-20-000033 · wf-form4_158216178578533.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,453 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,500 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mrs. McDowell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. F2 · price: The fair market value was determined on February 14, 2020 pursuant to the Plan. Read SEC document
December 31, 2019 Filed Jan 3, 2020 18:46 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	OtherCommon Stock	382	$10.82	$4,133.24	Disclosure SEC source: 0001479290-20-000004 · wf-form4_157809519931589.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,317 F1 · kind: These shares were acquired by Mrs. McDowell under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mrs. McDowell purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2019. Read SEC document
June 28, 2019 Filed Jul 2, 2019 21:14 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	OtherCommon Stock	1,000	$11.02	$11,024.50	Disclosure SEC source: 0001479290-19-000075 · wf-form4_156211644435237.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,935 F1 · kind: These shares were acquired by Ms. McDowell under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on June 28, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Ms. McDowell purchased the maximum number of shares allowable under the Issuer's Plan for the period ended June 30, 2019. Read SEC document
June 15, 2019 Filed Jun 17, 2019 20:30 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	Tax withholdingCommon Stock	1,383	$10.86	$15,019.38	Disclosure SEC source: 0001479290-19-000071 · wf-form4_156081780076449.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,935 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on June 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 16,000 shares. The RSA vests in four equal annual installments from June 15, 2018, subject to Ms. McDowell's Continuous Service (as defined in the Issuer's 2014 Inducement Plan (the Plan)) on each vesting date. F2 · price: The fair market value was determined on June 14, 2019, pursuant to the Plan. Read SEC document
January 24, 2019 Filed Jan 25, 2019 20:54 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantEmployee Stock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $17.23	$0.00	Disclosure SEC source: 0001479290-19-000016 · wf-form4_154846763329049.xml · derivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-23 F2 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 24, 2019, subject to Ms. McDowell's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document
January 24, 2019 Filed Jan 25, 2019 20:54 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0001479290-19-000016 · wf-form4_154846763329049.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,318 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from February 15, 2019, subject to Ms. McDowell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. Read SEC document
December 31, 2018 Filed Jan 2, 2019 20:05 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	OtherCommon Stock	818	$17.11	$13,996.39	Disclosure SEC source: 0001479290-19-000004 · wf-form4_154647754152580.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,818 F1 · kind: These shares were acquired by Ms. McDowell under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
May 01, 2018 Filed May 3, 2018 20:23 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantEmployee Stock Option (Right to Buy) · Derivative	110,000	$0.00 Strike: $28.30	$0.00	Disclosure SEC source: 0001479290-18-000062 · wf-form4_152539340405676.xml · derivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-04-30 F2 · derivative.exercise_date: The shares subject to the stock option shall vest over a period of four years commencing on May 1, 2018, with 25% vesting on the first anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Ms. McDowell's Continuous Service (as defined in the Plan) through each such vesting date. Read SEC document
May 01, 2018 Filed May 3, 2018 20:23 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0001479290-18-000062 · wf-form4_152539340405676.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: The shares subject to the Restricted Stock award shall vest in four (4) equal annual installments beginning from June 15, 2018, subject to Ms. McDowell's Continuous Service (as defined in the Issuer's 2014 Inducement Plan (the "Plan")) on each vesting date. Read SEC document
February 28, 2018 Filed Mar 2, 2018 00:12 UTC	CYTOKINETICS INC CYTK · Entity 3528	Tax withholdingCommon Stock	2,452	$7.75	$19,003.00	Disclosure SEC source: 0001061983-18-000017 · edgardoc.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,548 Read SEC document
February 27, 2018 Filed Mar 2, 2018 00:12 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (right to buy) · Derivative	14,774	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001061983-18-000017 · edgardoc.xml · derivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,774 Underlying: Common Stock · 14,774 shares Expires 2028-02-27 F2 · derivative.exercise_date: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. Read SEC document
February 27, 2018 Filed Mar 2, 2018 00:12 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantIncentive Stock Option (right to buy) · Derivative	15,226	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001061983-18-000017 · edgardoc.xml · derivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,226 Underlying: Common Stock · 15,226 shares Expires 2028-02-27 F2 · derivative.exercise_date: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. Read SEC document
February 27, 2018 Filed Mar 2, 2018 00:12 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	20,000	$0.00	$20.00	Disclosure SEC source: 0001061983-18-000017 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	77	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · derivative · entry 18 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921 Underlying: Common Stock · 77 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	77	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · derivative · entry 17 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998 Underlying: Common Stock · 77 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	653	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · derivative · entry 16 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,038 Underlying: Common Stock · 653 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	652	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · derivative · entry 15 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,691 Underlying: Common Stock · 652 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	625	$0.00 Strike: $6.37	$0.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · derivative · entry 14 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 625 shares Expires 2025-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	625	$0.00 Strike: $6.37	$0.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · derivative · entry 13 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 625 shares Expires 2025-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	625	$9.00	$5,625.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 12 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	625	$6.37	$3,981.25	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 11 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	625	$9.00	$5,625.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 10 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	625	$6.37	$3,981.25	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 9 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	653	$9.00	$5,877.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 8 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	653	$6.67	$4,355.51	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 7 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	652	$9.00	$5,868.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 6 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	652	$6.67	$4,348.84	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 5 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	77	$9.00	$693.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	77	$6.67	$513.59	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	77	$9.00	$693.00	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
January 16, 2018 Filed Jan 19, 2018 01:10 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	77	$6.67	$513.59	Disclosure SEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	77	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · derivative · entry 8 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075 Underlying: Common Stock · 77 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	653	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · derivative · entry 7 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,343 Underlying: Common Stock · 653 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	625	$0.00 Strike: $6.37	$0.00	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · derivative · entry 6 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Underlying: Common Stock · 625 shares Expires 2025-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	625	$6.37	$3,981.25	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 5 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	1,800	$13.00	$23,400.00	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,375 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	653	$6.67	$4,355.51	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	2,460	$12.90	$31,734.00	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,522 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
November 02, 2017 Filed Nov 7, 2017 01:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionCommon Stock	77	$6.67	$513.59	Disclosure SEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document
October 06, 2017 Filed Oct 10, 2017 23:20 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,507	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-17-000060 · edgardoc.xml · derivative · entry 25 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,152 Underlying: Common Stock · 1,507 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 06, 2017 Filed Oct 10, 2017 23:20 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	3,719	$0.00 Strike: $6.67	$0.00	Disclosure SEC source: 0001061983-17-000060 · edgardoc.xml · derivative · entry 24 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,996 Underlying: Common Stock · 3,719 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 06, 2017 Filed Oct 10, 2017 23:20 UTC	CYTOKINETICS INC CYTK · Entity 3528	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	6,357	$0.00 Strike: $6.37	$0.00	Disclosure SEC source: 0001061983-17-000060 · edgardoc.xml · derivative · entry 23 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,357 shares Expires 2025-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 06, 2017 Filed Oct 10, 2017 23:20 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	1,598	$15.70	$25,088.60	Disclosure SEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 22 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,771 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.